Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk

Journal of Clinical Investigation

Volumn 124, Issue 3, 2014, Pages 1037-1051

  Lien, Fleur ^a,b,c,d   Berthier, Alexandre ^a,b,c,d   Bouchaert, Emmanuel ^a,b,c,d   Gheeraert, Céline ^a,b,c,d   Alexandre, Jeremy ^a,b,c,d   Porez, Geoffrey ^a,b,c,d   Prawitt, Janne ^a,b,c,d   Dehondt, Hélène ^a,b,c,d   Ploton, Maheul ^a,b,c,d   Colin, Sophie ^a,b,c,d   Lucas, Anthony ^a,b,c,d   Patrice, Alexandre ^a,e   Pattou, Fraņois ^a,e   Diemer, Hélène ^f   Van Dorsselaer, Alain ^f   Rachez, Christophe ^g   Kamilic, Jelena ^h   Groen, Albert K ^h   Staels, Bart ^a,b,c,d   Lefebvre, Philippe ^a,b,c,d  

^a France   (France)

^b Faculté de Médecine de Lille Pôle Recherche ^*  (France)

^c UNIV LILLE   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e INSERM   (France)

^f INSTITUT DE RECHERCHES SUBATOMIQUES   (France)

^g CNRS   (France)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; BILE ACID; DNA TOPOISOMERASE; FARNESOID X RECEPTOR; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P160;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID HOMEOSTASIS; BILE ACID METABOLISM; BINDING SITE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; HEPATOMA CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CELL; INTRAHEPATIC CHOLESTASIS; LIVER CELL; LIVER INJURY; MASS SPECTROMETRY; METABOLIC REGULATION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADENYLATE KINASE; AMINO ACID SEQUENCE; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHOLESTASIS, INTRAHEPATIC; HEP G2 CELLS; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINES; LIVER; MALE; METFORMIN; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84896769099     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI68815     Document Type: Article

References (52)

1. Nguyen A, Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell Signal. 2008;20(12):2180-2197.
2. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147-191.
3. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 2004; 18(2):157-169.
4. Ananthanarayanan M, Li S, Balasubramaniyan N, Suchy FJ, Walsh MJ. Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1. J Biol Chem. 2004; 279(52):54348-54357.
5. Rizzo G, Renga B, Antonelli E, Passeri D, Pellicciari R, Fiorucci S. The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005;68(2):551-558.
6. Pineda Torra I, Freedman LP, Garabedian MJ. Identification of DRIP205 as a coactivator for the Farnesoid X receptor. J Biol Chem. 2004; 279(35):36184-36191.
7. Kemper JK. Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications. Biochim Biophys Acta. 2011;1812(8):842-850.
8. Inagaki T, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2(4):217-225.
9. Liu Y, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intraand extrahepatic cholestasis. J Clin Invest. 2003; 112(11):1678-1687.
10. Cui YJ, Aleksunes LM, Tanaka Y, Goedken MJ, Klaassen CD. Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol Sci. 2009;110(1):47-60.
11. Fiorucci S, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther. 2005;313(2):604-612.
12. Canto C, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458(7241):1056-1060.
13. Fulco M, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell. 2008;14(5):661-673.
14. Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem. 2008;283(41):27628- 27635.
15. Chopra AR, et al. Cellular energy depletion resets whole-body energy by promoting coactivatormediated dietary fuel absorption. Cell Metab. 2011; 13(1):35-43.
16. Duran-Sandoval D, et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes. 2004;53(4):890-898.
17. Surapureddi S, et al. Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha-interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc Natl Acad Sci U S A. 2002;99(18):11836-11841.
18. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8(10):774-785.
19. Reznick RM, Shulman GI. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol. 2006;574(pt 1):33-39.
20. Frankenberg T, Rao A, Chen F, Haywood J, Shneider BL, Dawson PA. Regulation of the mouse organic solute transporter α-β, Ostalpha-Ostbeta, by bile acids. Am J Physiol Gastrointest Liver Physiol. 2006; 290(5):G912-G922.
21. Kodiha M, Rassi JG, Brown CM, Stochaj U. Localization of AMP kinase is regulated by stress, cell density, and signaling through the MEK→ERK1/2 pathway. Am J Physiol Cell Physiol. 2007; 293(5):C1427-C1436.
22. Stein SC, Woods A, Jones NA, Davison MD, Carling D. The regulation of AMP-activated protein kinase by phosphorylation. Biochem J. 2000;345(pt 3):437-443.
23. Zhang Y, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006; 103(4):1006-1011.
24. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731-744.
25. Zollner G, et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol. 2006; 290(5):G923-G932.
26. Prawitt J, et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes. 2011;60(7):1861-1871.
27. Miralles-Linares F, Puerta-Fernandez S, Bernal-Lopez MR, Tinahones FJ, Andrade RJ, Gomez-Huelgas R. Metformin-induced hepatotoxicity. Diabetes Care. 2012;35(3):e21.
28. Stedman C, et al. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci U S A. 2006;103(30):11323-11328.
29. Schulz S, et al. Progressive stages of mitochondrial destruction caused by cell toxic bile salts. Biochim Biophys Acta. 2013;1828(9):2121-2133.
30. Hsu CC, et al. Mitochondrial dysfunction represses HIF-1alpha protein synthesis through AMPK activation in human hepatoma HepG2 cells. Biochim Biophys Acta. 2013;1830(10):4743-4751.
31. Orlov I, Rochel N, Moras D, Klaholz BP. Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA. EMBO J. 2012;31(2):291-300.
32. Berrabah W, Aumercier P, Lefebvre P, Staels B. Control of nuclear receptor activities in metabolism by post-translational modifications. FEBS Lett. 2011; 585(11):1640-1650.
33. Raichur S, et al. Identification and validation of the pathways and functions regulated by the orphan nuclear receptor, RORα1, in skeletal muscle. Nucleic Acids Res. 2010;38(13):4296-4312.
34. Hong YH, Varanasi US, Yang W, Leff T. AMPactivated protein kinase regulates HNF4α transcriptional activity by inhibiting dimer formation and decreasing protein stability. J Biol Chem. 2003; 278(30):27495-27501.
35. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24(1):49-57.
36. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 2006;126(4):789-799.
37. Woods A, et al. LKB1 is required for hepatic bile acid transport and canalicular membrane integrity in mice. Biochem J. 2011;434(1):49-60.
38. Park YJ, et al. Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis. Hepatology. 2008; 47(5):1578-1586.
39. Ananthanarayanan M, et al. Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):G771-G781.
40. Lefebvre B, et al. Proteasomal degradation of retinoid X receptor α reprograms transcriptional activity of PPARγ in obese mice and humans. J Clin Invest. 2010;120(5):1454-1468.
41. Desilets DJ, Shorr AF, Moran KA, Holtzmuller KC. Cholestatic jaundice associated with the use of metformin. Am J Gastroenterol. 2001;96(7):2257-2258.
42. Kutoh E. Possible metformin-induced hepatotoxicity. Am J Geriatr Pharmacother. 2005;3(4):270-273.
43. Nammour FE, Fayad NF, Peikin SR. Metformininduced cholestatic hepatitis. Endocr Pract. 2003; 9(4):307-309.
44. Biyyani RS, Battula S, Erhardt CA, Korkor K. Metformin-induced cholangiohepatitis. BMJ Case Rep. 2009;2009:bcr0920080950.
45. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009;9(5):407-416.
46. Foretz M, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/ AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355-2369.
47. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494(7436):256-260.
48. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262.
49. Lamia KA, et al. AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science. 2009;326(5951):437-440.
50. Rachez C, et al. A novel protein complex that interacts with the vitamin D-3 receptor in a liganddependent manner and enhances VDR transactivation in a cell-free system. Genes Dev. 1998; 12(12):1787-1800.
51. Flajollet S, Lefebvre B, Rachez C, Lefebvre P. Distinct roles of the steroid receptor coactivator 1 and of MED1 in retinoid-induced transcription and cellular differentiation. J Biol Chem. 2006; 281(29):20338-20348.
52. Sacchetti P, Carpentier R, Segard P, Olive-Cren C, Lefebvre P. Multiple signaling pathways regulate the transcriptional activity of the orphan nuclear receptor NURR1. Nucleic Acids Res. 2006; 34(19):5515-5527.